Association of pS2 (TFF1) release with breast tumour proliferative rate: In vitro and in vivo studies

Cell Proliferation

Volumn 32, Issue 2-3, 1999, Pages 107-118

  Reshkin, S J ^a   Tedone, T ^b   Correale, M ^b   Mangia, A ^b   Casavola, V ^a   Paradiso, A ^b  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PROTEIN PS2;

ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNORADIOMETRIC ASSAY; PROTEIN SECRETION; SERUM;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0032876667     PISSN: 09607722     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2184.1999.32230107.x     Document Type: Article

References (37)

1. VAN AGTHOVEN T, VAN AGTHOVEN TL, DEKKER A, FOEKENS JA, DORSSERS LC. (1994) Induction of estrogen indipendence of ZR-751 human breast cancer cells by epigenetic alterations. Mol. Endocrinol. 8, 1474.
2. BESSE G, KWIATKOWSKI F, GAILLARD G et al. (1995) PS2 as a prognostic factor in 1065 cases of human breast cancer. Bull. Cancer 81, 289.
3. CAPPELLETTI V, CORADINI D, SCANZIANI E, BENINI E, SILVESTRINI R, DI FRONZO G. (1992) Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur. J. Cancer 28, 1315.
4. CAVAILLES V, GARCIA M, ROCHEFORT H, (1989) Regulation of cathepsin D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol. Endocrinol. 3, 552.
5. CORREALE M, PARADISO A, ABBATE I et al. (1993) Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity. Tumor Biol. 14, 30.
6. EORTC BREAST CANCER COOPERATIVE GROUP. (1980) Revision of the standards for the assessment of hormone receptor in human breast cancer. Eur. J. Cancer 16, 1513.
7. EVANS CW. (1991) The Metastatic Cell. Behaviour and Biochemistry. London: Chapman and Hall.
8. FOEKENS JA, PORTENGEN H, LOOK MP et al. (1994) Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br. J. Cancer 70, 1217.
9. FOEKENS JA, RIO MC, SEGUIN P et al. (1990) Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res. 50, 3832.
10. FOEKENS JA, VAN PUTTEN WLJ, PORTENGEN H et al. (1993) Prognostic value of pS2 and Cathepsin D in 710 human primary breast tumors: multivariate analisys. J. Clin. Oncol. 11, 899.
11. GION M, MIONE R, PAPPAGALLO GL et al. (1993) pS2 in breast cancer - alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br. J. Cancer 68, 374.
12. HENRY JA, PIGGOTT NH, MALLICK VK et al. (1991) PNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br. J. Cancer 63, 615.
13. KAYADEMIR T, SILVA ED, PUSCH C, BECK S, MACHADO JC, GOTT P. (1998) A novel 25 bp tandem repeat within the human trefoil peptide gene TTF2 in 21q22.3: polymorphism and mammalian evolution. European J. Human Genet. 6, 121.
14. KIDA N, YOSHIMURA T, MORI K, HAYASHI K. (1989) Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells (MCF-7). Cancer Res. 49, 3494.
15. LIPPMAN ME, DICKSON RB, KASIOL A et al. (1986) Autocrine and paracrine growth regulation of human breast cancer. J. Steroid Biochem. 24, 147.
16. MANNING DL, ROBERTSON JFR, ELLIS IO et al. (1994) Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement. Eur. J. Cancer 30, 675.
17. MARCHBANK T, WESTLEY BR, MAY FE, CALNAN DP, PLAYFORD RJ. (1998) Dimerization of human pS2 plays a key role in its protective/healing effects. J. Pathol 182 (2), 153-158.
18. MARSIGLIANTE S, MOTTAGHI A, MUSCELLA A, CIARDO V, LEO G, STORELLI C. (1995) Effect of tumor size on the association between pS2 and Cathepsin D in primary breast cancer. Int. J. Oncol. 6, 69.
19. MIYASHITA S, HIROTA M, YAMAMOTO T, SHIROYAMA C, FURUKAWA Y, HAYASHI K. (1994) Effect of basic fibroblast growth factor on synthesis/secretion of pS2 protein by human breast cancer cells (MCF-7). Eur. J. Biochem. 225, 1041.
20. NAKAZATO H, EDMONDS M, KOPP DW. (1974) Differential metabolism of large and small poly (A) sequences in the heterogeneous nuclear RNA of HeLa Cells. Proc. Natl. Acad. Sci. USA 71, 200.
21. NERI C, COLOMB E, ROUX-DOSSETO M, MARTIN PM. (1991) Distinct effects of gonadotropin-releasing hormone analogs and 4-hydroxytamoxifen on pS2 mRNA expression with respect to cell proliferation in MCF7 breast cancer cells. Anticancer Res. 11, 411.
22. NUNEZ AM, BERRY M, IMLER JL, CHAMBON P. (1989) The 5′ flanking region of pS2 gene contains a complex enhancer region responsive to estrogens, epidermal growth factor, a tumor promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO. J. 8, 823.
23. NUNEZ AMV, JAKOWLE SB, BRIAND JP et al. (1987) Characterization of the estrogen-induced pS2 protein secreted by the humen breast cancer cell line MCF7. Endocrinology 121, 1759.
24. PAGLIACCI MC, TOGNELLINI R, GRIGNANI F, NICOLETTI I. (1991) Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMC 201-995: effects on cell cycle parameters and apoptotic cell death. Endocrinol. 129, 2555.
25. PREDINE J, SPYRATOS F, PRUD'HOMME JF. (1992) Enzyme-linked immunosorbent assay of pS2 in breast cancer. benign tumors, and normal breast tissues. Cancer 69, 2116.
26. RAJAKARIAR R, WALKER RA. (1995) Pathogical and biological features of mammographically detected invasive breast carcinomas. Br. J. Cancer 71, 150.
27. RIO MC, CHAMBON P. (1990) The pS2 gene, mRNA and protein. A potential marker for human breast cancer cell line (review). Cancer Cells 2, 269.
28. SAUER T, NAESS O. (1994) Expression of the pS2 protein and correlation with estrogen receptor status in fine-needle aspirates from breast carcinomas. Diagn. Cytopathol. 11, 165.
29. SCHWARTZ LH, KOERNER FC, EDGERTON SM et al. (1991) pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 51, 624.
30. SOUBEYRAN I, QUENEL N, COINDRE JM et al. (1996) pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br. J. Cancer 74, 1120.
31. SOUBEYRAN I, WAFFLART J, BONICHON F et al. (1995). Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res. Treat. 34, 119.
32. SOULE HD, VASQUEZ J, LONG A, ALBERT S, BRENNAN M. (1973) A human cell line from a pleural effusion from a breast carcinoma. J. Natl. Cancer Inst. 51, 1409.
33. TEDONE T, CORREALE M, BARBAROSSA G, CASAVOLA V, PARADISO A, RESHKIN SJ. (1997) Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion. FASEB J. 11, 785.
34. TEDONE T, CORREALE M, PARADISO A, RESHKIN SJ. (1996) Differential responsiveness of proliferation and cytokeratin release to stripped serum and oestrogen in the human breast cancer cell line, MCF-7. Eur. J. Cancer 32A, 849.
35. THOMPSON AM, HAWKINS AM, ELTON RA, STEEL CM, CHETTY U, CHARTER DC. (1993) pS2 is an independent factor of good prognosis in primary breast cancer. Br. J. Cancer 68, 93-96.
36. THOR ADF, KOERNER C, EDGERTON SM, WOOD WC, STRACHER MA, SCHWARTZ LH. (1992) pS2 expression in primary breast carcinomas: relationship to clinical and histological feature and survival. Breast Cancer Res. Treat. 21, 111.
37. + exchangers. Physiol. Reviews 77, 51.